10.6084/m9.figshare.c.3688210_D2.v1 Antonino Musolino Antonino Musolino Mario Campone Mario Campone Patrick Neven Patrick Neven Neelima Denduluri Neelima Denduluri Carlos Barrios Carlos Barrios Javier Cortes Javier Cortes Kimberly Blackwell Kimberly Blackwell Hatem Soliman Hatem Soliman Zsuzsanna Kahan Zsuzsanna Kahan Hervé Bonnefoi Hervé Bonnefoi Matthew Squires Matthew Squires Yong Zhang Yong Zhang Stephanie Deudon Stephanie Deudon Michael Shi Michael Shi Fabrice André Fabrice André Additional file 2: Table S1. of Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy Springer Nature 2017 Dovitinib TKI285 Fulvestrant FGF FGFR Breast cancer Endocrine resistance 2017-02-10 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_2_Table_S1_of_Phase_II_randomized_placebo-controlled_study_of_dovitinib_in_combination_with_fulvestrant_in_postmenopausal_patients_with_HR_HER2_breast_cancer_that_had_progressed_during_or_after_prior_endocrine_therapy/4640344 Dose changes and dose delays by treatment arm. Table S2. Adverse events leading to study drug discontinuation regardless of study drug relationship. Table S3. Study center. (DOCX 17 kb)